

Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer

Information for the public

Published: 12 November 2025

www.nice.org.uk

Darolutamide (Nubeqa) with androgen deprivation therapy is available on the NHS. It is a possible treatment for hormone-sensitive metastatic prostate cancer in adults when docetaxel is not suitable.

If you are not eligible for darolutamide with androgen deprivation therapy but are already having it, you should be able to continue until you and your healthcare professional decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on shared decision making](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on prostate cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Prostate Cancer UK](#), 0800 074 8383
- [Tackle Prostate Cancer](#), 0800 035 5302
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-7300-2